What question did this study set out to answer?

To evaluate the immunogenicity, expression patterns, and protective efficacy of recombinant Echinococcus multilocularis calreticulin as a candidate vaccine against alveolar echinococcosis in BALB/c mice.

June 15, 2022Open Access

Immunization with rEmCRT provides protection against Echinococcus multilocularis infection in BALB/c mice

View Full Paper

Ask AI

Bookmark

Authors

LCLujuan ChenXiamen University ZCZhe ChengXiamen University SXSiqi XianNanjing Normal University

Discussion

Member takes

Implication

Preclinical study demonstrates 43.7% protection via recombinant calreticulin vaccination in BALB/c mice, highlighting a novel candidate against alveolar echinococcosis.

Key Points

To evaluate the immunogenicity, expression patterns, and protective efficacy of recombinant Echinococcus multilocularis calreticulin as a candidate vaccine against alveolar echinococcosis in BALB/c mice.
Cloned and expressed recombinant calreticulin (rEmCRT) in Escherichia coli BL21 to analyze calcium-binding properties and native expression in protoscoleces and vesicles.
Immunized BALB/c mice with rEmCRT formulated with Freund's adjuvant and challenged them with E. multilocularis protoscoleces.
Evaluated antigen-specific humoral responses (IgG1 and IgG2a) and splenic cytokine profiles (IFN-γ, IL-2, IL-4, IL-5, IL-10) to assess protective efficacy.
EmCRT demonstrated calcium-binding ability and localized to the larval surface as well as secretomes of metacestode vesicles and protoscoleces.
Immunization induced robust IgG1 and IgG2a responses with an elevated IgG1/IgG2a ratio indicating Th2 predominance, while splenocytes secreted high levels of both Th1 and Th2 cytokines.
Vaccinated mice achieved approximately 43.7% protective immunity against E. multilocularis protoscolex infection.

Cite This Study

Chen et al. (2022) studied this question.

synapsesocial.com/papers/6a9054786bfd95d7bd4ddade https://doi.org/10.21203/rs.3.rs-1740725/v1

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates 43.7% protection via recombinant calreticulin vaccination in BALB/c mice, highlighting a novel candidate against alveolar echinococcosis.

Immunization with rEmCRT provides protection against Echinococcus multilocularis infection in BALB/c mice

Discussion

Member takes

Implication

Key Points

Cite This Study

Immunization with rEmCRT provides protection against Echinococcus multilocularis infection in BALB/c mice

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider